Side-by-side research comparison of CJC-1295 and Ipamorelin across our PubMed, ClinicalTrials.gov, and EuropePMC corpus. 1 head-to-head study plus 25 on CJC-1295 and 45 on Ipamorelin.
| CJC-1295 | Ipamorelin | |
|---|---|---|
| Drug class | ghrh analog | ghrh secretagogue, ghrelin mimetic |
| Studies in corpus | 25 | 45 |
| Highest evidence tier | rct | rct |
| Evidence tier mix | in vitro · 6 preclinical animal · 2 rct · 2 other · 13 review · 1 | other · 12 preclinical animal · 22 rct · 4 in vitro · 5 review · 1 |
| Studies with explicit sample size | 0 | 3 |
| Head-to-head studies in corpus | 1 | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real CJC-1295 and Ipamorelin batches we've tested. Aggregate, public data — cross-reference against the studies below.
We tested 966 CJC-1295 batches across 373 manufacturers, 97.77% avg purity.
We tested 1802 Ipamorelin batches across 638 manufacturers, 99.52% avg purity.
We hold deeper lab coverage on Ipamorelin (1802 batches tested). Ipamorelin edges ahead on average measured purity (97.77% vs 99.52%) — a narrow gap; weigh it against failed-batch and underdose counts above.
Studies in our corpus that mention both CJC-1295 and Ipamorelin — the gold-standard direct comparison evidence.
This review highlights a critical distinction for peptide users and clinicians: only GLP-1R agonists currently possess reproducible, high-quality evidence for a specific musculoskeletal indication (knee osteoarthritis symptom relief). For other widely promo…
Looking for vendor-level purity, endotoxin, and HPLC data on CJC-1295 or Ipamorelin? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.